U.S. Markets closed
  • S&P 500

    3,768.25
    -27.29 (-0.72%)
     
  • Dow 30

    30,814.26
    -177.24 (-0.57%)
     
  • Nasdaq

    12,998.50
    -114.10 (-0.87%)
     
  • Russell 2000

    2,123.20
    -32.15 (-1.49%)
     
  • Crude Oil

    52.04
    -0.32 (-0.61%)
     
  • Gold

    1,827.70
    -2.20 (-0.12%)
     
  • Silver

    24.83
    -0.04 (-0.14%)
     
  • EUR/USD

    1.2082
    -0.0082 (-0.6766%)
     
  • 10-Yr Bond

    1.0970
    -0.0320 (-2.83%)
     
  • Vix

    24.34
    +1.09 (+4.69%)
     
  • GBP/USD

    1.3591
    -0.0049 (-0.3574%)
     
  • USD/JPY

    103.8410
    -0.0010 (-0.0010%)
     
  • BTC-USD

    36,227.92
    +1,227.25 (+3.51%)
     
  • CMC Crypto 200

    701.93
    -33.21 (-4.52%)
     
  • FTSE 100

    6,735.71
    -66.25 (-0.97%)
     
  • Nikkei 225

    28,519.18
    -179.12 (-0.62%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BIIB, YY and QSR

·3 min read

NEW YORK, NY / ACCESSWIRE / January 4, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Biogen Inc. (NASDAQ:BIIB)
Class Period: October 22, 2019 - November 6, 2019
Lead Plaintiff Deadline: January 12, 2021

The complaint alleges that during the class period Biogen Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the larger dataset did not provide necessary data regarding aducanumab's effectiveness; (2) the EMERGE study did not and would not provide necessary data regarding the effectiveness of aducanumab, Biogen's investigational human monoclonal antibody studied for the treatment of early Alzheimer's disease; (3) the PRIME study did not and would not provide necessary data regarding aducanumab's effectiveness; (4) the data provided by the Company to the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee did not support finding efficacy of aducanumab; and (5) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Learn about your recoverable losses in BIIB: http://www.kleinstocklaw.com/pslra-1/biogen-inc-loss-submission-form?id=11925&from=1

Joyy Inc. (NASDAQ:YY)
Class Period: April 28, 2016 - November 18, 2020
Lead Plaintiff Deadline: January 19, 2021

The YY lawsuit alleges Joyy Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (1) JOYY dramatically overstated its revenues from live streaming sources; (2) The majority of users at any given time were bots; (2) the Company utilized these bots to effect a roundtripping scheme that Manufactured the false appearance of revenues; (3) the Company overstated its cash reserves; (4) the Company's acquisition of Bigo was largely contrived to benefit corporate insiders; and (5) as a result, Defendants' public statements were materially false and/or Misleading at all relevant times.

Learn about your recoverable losses in YY: http://www.kleinstocklaw.com/pslra-1/joyy-inc-loss-submission-form?id=11925&from=1

Restaurant Brands International Inc. (NYSE:QSR)
Class Period: April 29, 2019 - October 28, 2019
Lead Plaintiff Deadline: February 19, 2021

The complaint alleges that throughout the class period Restaurant Brands International Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Winning Together Plan was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (2) the Tims Rewards loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

Learn about your recoverable losses in QSR: http://www.kleinstocklaw.com/pslra-1/restaurant-brands-international-inc-loss-submission-form?id=11925&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/623038/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-BIIB-YY-and-QSR